SEVELAMER TARO 2.4 G

Երկիր: Իսրայել

Լեզու: անգլերեն

Աղբյուրը: Ministry of Health

Ակտիվ բաղադրիչ:

SEVELAMER CARBONATE ANHYDROUS

Հասանելի է:

TARO INTERNATIONAL LTD, ISRAEL

ATC կոդը:

V03AE02

Դեղագործական ձեւ:

POWDER FOR SUSPENSION

Կազմը:

SEVELAMER CARBONATE ANHYDROUS 2.4 G

Կառավարման երթուղին:

PER OS

Ռեկվիզորի տեսակը:

Required

Պատրաստված է:

SYNTHON HISPANIA S.L., SPAIN

Թերապեւտիկ տարածք:

SEVELAMER

Թերապեւտիկ ցուցումներ:

For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

Հաստատման ամսաթիվը:

2020-06-17

Տեղեկատվական թերթիկ

Page 1 of 6
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed with a doctor’s prescription only
SEVELAMER TARO 800 MG
TABLETS
ACTIVE INGREDIENT: Each film-coated tablet
contains:
sevelamer carbonate anhydrous 800 mg
SEVELAMER TARO 2.4 G
POWDER FOR ORAL SUSPENSION
ACTIVE INGREDIENT: Each sachet of powder
contains:
sevelamer carbonate anhydrous
2.4 gram
Inactive ingredients and allergens: See the section 'Important
information about some of this
medicine’s ingredients', and section 6 ‘Additional information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains
concise information about this medicine. Keep the leaflet. You may
need to read it again.
If you have any further questions, consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It may harm
them, even if it seems to you that their illness is similar to yours.
1. WHAT IS THIS MEDICINE INTENDED FOR?
This medicine is intended for:
•
Controlling high levels of phosphate in blood of adult patients who
are on dialysis
(hemodialysis or peritoneal dialysis).
•
Controlling high levels of phosphate in blood of adult patients with a
chronic kidney
disease who are not on dialysis, have a blood phosphorus level equal
to or above 1.78
mmol/l.
The medicine should be used with other treatments such as calcium
supplements and
vitamin D to prevent the development of bone disease due to kidney
disease.
THERAPEUTIC GROUP: phosphate binders.
Sevelamer carbonate binds phosphate from food in the digestive tract
and in this way reduces
serum phosphorus levels in the blood.
2. BEFORE USING THIS MEDICINE
DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient sevelamer or to
any of the other
ingredients in this medicine (see section 6).
•
You have low blood phosphate levels (the doctor will check this for
you).
•
You have a blockage in your bowel.
Page 2 of 6
SPECIAL W